Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat

I keep buying Pfizer (NYSE:PFE | PFE Price Prediction) every time my brokerage cash builds up, and I am not slowing down. The market is treating this company like a value trap because COVID revenue is rolling off. I am treating it like a cash machine that just bought itself three extra years of patent life on one of its highest-margin franchises and is using the breathing room to fund the deepest late-stage pipeline I have seen from this company in a decade.

The conviction starts with a number that does not lie. I am collecting a 6.80% dividend yield on shares trading near $25.21, backed by a free cash flow yield of 6.32%. Pfizer paid out $2.4 billion in dividends in Q1 2026 alone, and the quarterly payout has climbed from $0.30 in 2016 to $0.43 today. That is income I can plan a retirement around.

The Patent Settlement Wall Street Slept On

The catalyst that flipped my conviction from cautious to aggressive was the Vyndamax patent settlement extending U.S. exclusivity to June 2031. Wall Street had a devastating 2028/2029 patent cliff baked into the share price. CEO Albert Bourla told investors on the Q1 call that “starting in 2029, we will enter a five-year period of high single-digit revenue CAGR” and that the $17 billion LOE estimate is now more like $14 to $15 billion. That is billions of dollars in high-margin cash flow that the consensus model had erased. It is back.

The operating business is already proving the thesis. Q1 2026 revenue came in at $14.45B, beating the $13.80B consensus by 4.70%, with adjusted diluted EPS of $0.75 marking the fifth consecutive EPS beat. The non-COVID engine is firing on every cylinder: Padcev +39%, Nurtec ODT +41%, Eliquis +13%, Abrysvo +37%, Orgovyx +43%, and the launched and acquired portfolio grew 22% operationally. Management reaffirmed full-year 2026 guidance of $59.5B to $62.5B in revenue and $2.80 to $3.00 in adjusted EPS.

Then there is the pipeline I am effectively getting for free at a forward P/E of 9. Pfizer is launching roughly 20 pivotal studies in 2026, the Lyme disease vaccine candidate posted 73.2% efficacy in Phase 3, and the Metsera acquisition hands me ultra-long-acting GLP-1 optionality in the obesity market. Bourla himself has been accumulating Phantom Stock Units every month from March through June 2026, at prices ranging from $25.33 to $28.08.

The Risk I Am Not Pretending Away

The real risk is policy and pricing. Comirnaty fell 59% and Paxlovid fell 63% in Q1, generic and biosimilar competition will pull roughly $1.5B off the top line in 2026, and Most-Favored-Nation pricing plus the TrumpRx platform could compress margins. I am watching it closely. The reason it does not derail my thesis: the dividend is covered by free cash flow, the Vyndamax extension fills the very gap these headwinds create, and the $7.2B cost savings program protects EPS while the pipeline matures.

Wall Street walked away from a $143.7 billion diversified pharma giant paying me almost 7% to wait. I will keep clicking buy until that math breaks.

Contact [email protected] for any questions or corrections.